← Todos los Artículos

Peptides & Longevidad: Current Research

Revisado médicamente por el equipo clínico de Irvine Health. La información refleja investigaciones publicadas al 2026-04-01.

Solo contenido educativo. El siguiente artículo se basa en investigaciones científicas publicadas y se proporciona con fines informativos. No constituye consejo médico, diagnóstico ni recomendación de tratamiento. Las respuestas individuales a cualquier terapia varían. Todos los protocolos de péptidos en Irvine Health están disponibles solo después de una video consulta con un médico con licencia y una receta escrita.

Longevidad science has accelerated dramatically over the past decade, with peptides emerging as a class of molecules with potential relevance to several cellular and systemic aging mechanisms. Unlike pharmacological interventions that target single pathways, some peptides appear to interact with pleiotropic systems — including epigenetic regulation, mitochondrial function, telomere biology, and immune senescence — that converge in the biology of aging. This article surveys the current research landscape with an emphasis on evidence quality.

Key Peptides in Longevidad Research

Epitalón (Epitalon)

Khavinson et al., publicaciones múltiples (1999–2010)

El Epitalón (Ala-Glu-Asp-Gly) es un tetrapéptido sintético desarrollado por Vladimir Khavinson en el Instituto de Bioregulación y Gerontología de San Petersburgo. Los grupos de investigación rusos han publicado estudios que sugieren que el Epitalón puede activar la telomerasa en células somáticas humanas — potencialmente extendiendo la longitud de los telómeros — y reducir marcadores de estrés oxidativo en modelos animales envejecidos. Un artículo clave de Khavinson et al. (2003) reportó la activación de telomerasa en fibroblastos fetales humanos. Sin embargo, la mayor parte de esta investigación proviene de una sola tradición de laboratorio y no ha sido replicada de forma independiente en ensayos revisados por pares occidentales.

Aging and Neuroendocrine Function — Anisimov et al.

Los estudios en animales sugieren que el Epitalón puede modular la secreción circadiana de melatonina a través de efectos sobre la glándula pineal, y puede reducir la incidencia de tumores espontáneos en roedores envejecidos. Estos hallazgos, aunque intrigantes, siguen siendo preclínicos y requieren validación prospectiva en ensayos humanos.

GHK-Cu (Copper Peptide)

Pickart L, Margolina A — Revisión 2018

GHK-Cu disminuye naturalmente de aproximadamente 200 ng/mL en adultos jóvenes a unos 80 ng/mL en personas mayores. Los análisis genómicos (Pickart 2012) sugieren que GHK-Cu puede modular la expresión de más de 4,000 genes humanos — incluyendo genes involucrados en la síntesis de colágeno, defensa antioxidante y remodelación tisular. Si bien la amplitud de estas afirmaciones requiere interpretación cautelosa, GHK-Cu tiene una literatura de investigación independiente más sustancial que muchos péptidos de longevidad.

MOTS-c

Lee et al., Cell Metab (2015)

MOTS-c es un péptido derivado de la mitocondria codificado dentro del genoma mitocondrial. La investigación inicial encontró que regula la homeostasis metabólica a través de la activación de AMPK y mejora la sensibilidad a la insulina en modelos de ratón de obesidad inducida por dieta. Trabajos posteriores sugirieron que los niveles de MOTS-c disminuyen con la edad en humanos y que el MOTS-c circulante se correlaciona con marcadores de salud metabólica — convirtiéndolo en un candidato para la investigación sobre envejecimiento metabólico.

The Evidence Challenge in Longevidad Medicine

Longevidad is a uniquely difficult endpoint to study in clinical trials. Human lifespan trials would require decades of follow-up, vast sample sizes, and enormous cost. The research community therefore relies on surrogate markers — telomere length, epigenetic clocks, inflammatory markers, metabolic function — which correlate with aging but do not definitively prove lifespan extension. Patients and providers must navigate this uncertainty together.

La plausibilidad mecanicista, la evidencia preclínica y los datos tempranos de biomarcadores informan las decisiones clínicas en la medicina de longevidad, pero la ausencia de datos de ECA a largo plazo es una limitación genuina que cualquier discusión honesta de consentimiento informado debe reconocer.

Referencias

  1. Khavinson VKh, et al. Peptide regulation of aging. Adv Gerontol. 2003;11:15-22.
  2. Pickart L, Margolina A. Regenerativo and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987.
  3. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
  4. Anisimov VN, et al. Effect of Epitalon on the life span of old female C3H/He mice with spontaneous mammary tumors. Neuro Endocrinol Lett. 2002;23(2):138-41.
📋

¿Interesado en este protocolo?

Todas las terapias con péptidos en Irvine Health requieren una videoconsulta con un médico con licencia y una receta escrita. No se dispensa ningún tratamiento sin una evaluación médica completa. Únase a la lista de espera para ser contactado cuando comencemos a aceptar nuevos pacientes en su estado.

Explorar Más Artículos

Explore nuestra biblioteca completa de investigaciones basadas en evidencia sobre péptidos.

Ver Todos los Artículos

*The assessment made available on the Irvine Health website does not create a doctor-patient relationship between the individual completing the assessment and Irvine Health. Irvine Health partners with a network of US-licensed doctors that adhere to rigorous medical protocols designed for patient safety. The answers an individual provides to the Irvine Health assessment consequently determine if the individual is screened out of eligibility for medication, and an Irvine Health clinician will meet with an individual after checkout to determine if they qualify for a prescription. Irvine Health clinicians retain the decision to prescribe compounded medications to patients.

All claims and benefits on this website refer to self-reported data from customers on a treatment plan that includes compounded medications and consultations with medical professionals. Customers reported their weight on their initial medical intake questionnaire every 3–4 weeks thereafter. Results from compounded medications found on the Irvine Health platform may vary and be affected by an individual’s adherence to the program and their clinician’s recommendations. Compounded peptides and GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality. The decision to use compounded drugs is guided by the licensed provider’s medical judgment, which is informed by a telehealth consultation and medical history.

We encourage all prospective users of compounded medications to speak with their provider about the specific risks and benefits that may come with the use of compounded medication. Irvine Health does not produce compounded medications, and individuals may receive medication that looks different than what is portrayed on the website.

Pharmacy Providers

We are partnered with multiple USA certified pharmacies to bring the best product and overall experience to our membership. Our team meets regularly with pharmacies to discuss any product shortages, shipping delays, and get updated reports on their medication testing.

*Results vary based on starting weight and program adherence. Inches lost from hips, waist, chest, thighs, and arms in the first month. Patients exercised daily and ate a reduced-calorie diet. Their fat loss is not typical. Results may vary. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. Consult a healthcare professional before using medication or starting any weight loss program. *Based on the average weight loss as reported by patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity.

Medication is included in the cost of the Irvine Health Program. Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss. The trademarks, service marks, trade names (Wegovy®, Ozempic®), and products displayed on this Internet site are protected and belong to their respective owners. Medical treatment is provided by Irvine Health affiliated physicians and licensed professional corporations. No data, photos, claims, or any other information is associated with results derived from clinical trials, studies, or public information and is always representative of Irvine Health patient experience.

Certain materials on this website, including text, images, and other media, may be generated or enhanced using artificial intelligence technologies. No representation or warranty is made regarding the accuracy, completeness, or reliability of such content.

© 2026 Irvine Health LLC. All rights reserved. 19200 Von Karman Avenue, 4th, 5th, and 6th Floors, Irvine, CA 92612.